EIF2AK3 and central nervous system cancer: We found the expression of EIF2AK3 protein was significantly higher in WHO grades III (P < 0.05) and IV gliomas (P < 0.001) compared to WHO II gliomas (P < 0.05); However, the difference in EIF2AK3 protein expression between WHO II glioma and para-carcinoma tissues were not significant (Figure 8C).